Evidence map›Paper›PMID 42280253›Full record

ArticleMolecules (Basel, Switzerland)2026

Meijia Chen, Yu Zhu, Jianglong Chen, Rujie Zhou, Guang Li

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meijia ChenYunnan Branch, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Xishuangbanna 666100, China.
Yu ZhuInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.ORCID 0009-0008-5065-325X
Jianglong ChenYunnan Branch, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Xishuangbanna 666100, China.
Rujie ZhouYunnan Branch, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Xishuangbanna 666100, China.
Guang LiYunnan Branch, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Xishuangbanna 666100, China.ORCID 0000-0002-2393-5269

Funding

Chinese Academy of Medical Sciences (CAMS) Science and Technology Innovation Project for Medicine and Health 2021-I2M-1-031the Major Science and Technology Special Project of Yunnan Province 202402AA310041Yunnan Science and Technology Talent and Platform Program 202405AF140073
6 · The paper itself

Abstract

Cisplatin-induced acute kidney injury (AKI) poses a significant clinical challenge lacking specific therapeutic drugs.

Indexed as

Acute Kidney InjuryCisplatinFlavonoidsPlant ExtractsAnimalsDisease Models, AnimalKidneyMaleMiceMolecular Docking SimulationNetwork PharmacologySignal TransductionCisplatinFlavonoidsPlant Extractsacute kidney injury (AKI)Arundina graminifoliacisplatinnetwork pharmacologypathological targeted recruitmentpharmacodynamic material basisUPLC-Q-TOF-MS/MS

Identifiers

PMID42280253
PMCPMC13257526

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.